We are live on ! Find out more
CM

CM Management Portfolio holdings

AUM $120M
1-Year Est. Return 37.12%
This Fund
S&P 500
This Quarter Est. Return
-2.07%
1 Year Est. Return
+37.12%
3 Year Est. Return
+141.34%
5 Year Est. Return
+139.46%
10 Year Est. Return
–
AUM
$89.6M
AUM Growth
-$4.37M
Cap. Flow
+$640K
Cap. Flow %
0.71%
Top 10 Hldgs %
36.69%
Holding
74
New
5
Increased
31
Reduced
13
Closed
3

Top Buys

1
JPM icon
JPMorgan Chase
JPM
+$1.15M
2
FDX icon
FedEx
FDX
+$1.06M
3
WBA
Walgreens Boots Alliance
WBA
+$926K
4
AI icon
C3.ai
AI
+$897K
5
B
Barrick Mining
B
+$868K

Top Sells

1
CYTK icon
Cytokinetics
CYTK
+$2.41M
2
PTCT icon
PTC Therapeutics
PTCT
+$1.8M
3
CADE
Cadence Bank
CADE
+$1.64M
4
TALO icon
Talos Energy
TALO
+$1.34M
5
PAGP icon
Plains GP Holdings
PAGP
+$1.15M

Sector Composition

1 Healthcare 37.28%
2 Financials 10.8%
3 Energy 9.75%
4 Industrials 9.02%
5 Technology 7.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALCO icon
1
Alico
ALCO
$305M
$4.94M 5.52%
175,000
– –
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$4.7M 5.24%
450,000
– –
NHC icon
3
National Healthcare
NHC
$3.57B
$3.8M 4.24%
60,000
+4,000
+7% +$278K
ARKR icon
4
Ark Restaurants
ARKR
$21.1M
$3.35M 3.73%
180,000
+43,000
+31% +$849K
RLGT icon
5
Radiant Logistics
RLGT
$438M
$3.1M 3.46%
545,000
+10,000
+2% +$70.3K
TGB
6
Trekor Metals
TGB
$2.5B
$2.85M 3.18%
2,500,000
– –
NMRK icon
7
Newmark Group
NMRK
$2.8B
$2.62M 2.92%
325,000
– –
TALO icon
8
Talos Energy
TALO
$2.46B
$2.58M 2.88%
155,000
-75,000
-33% -$1.34M
SFE
9
DELISTED
Safeguard Scientifics, Inc.
SFE
$2.5M 2.8%
671,671
– –
CYTK icon
10
Cytokinetics
CYTK
$11B
$2.42M 2.7%
50,000
-50,000
-50% -$2.41M
IMGN
11
DELISTED
Immunogen Inc
IMGN
$2.39M 2.67%
500,000
+25,000
+5% +$132K
DRRX
12
DELISTED
DURECT Corp
DRRX
$2.17M 2.42%
375,000
– –
SWN
13
DELISTED
Southwestern Energy Company
SWN
$2.14M 2.39%
350,000
+50,000
+17% +$346K
BGC icon
14
BGC Group
BGC
$5.41B
$2.12M 2.37%
675,000
– –
PLPC icon
15
Preformed Line Products
PLPC
$1.63B
$1.99M 2.22%
28,000
– –
CHRS icon
16
Coherus Oncology
CHRS
$214M
$1.92M 2.15%
200,000
– –
RNWK
17
DELISTED
RealNetworks Inc
RNWK
$1.8M 2.01%
2,593,688
– –
ARKO icon
18
ARKO Corp
ARKO
$891M
$1.78M 1.99%
190,000
-35,000
-16% -$332K
FNF icon
19
Fidelity National Financial
FNF
$14B
$1.63M 1.82%
46,800
+20,800
+80% +$777K
RIGL icon
20
Rigel Pharmaceuticals
RIGL
$764M
$1.53M 1.71%
130,000
– –
BATL icon
21
Battalion Oil
BATL
$37.9M
$1.49M 1.66%
125,000
+10,000
+9% +$113K
AVIR icon
22
Atea Pharmaceuticals
AVIR
$385M
$1.42M 1.59%
250,000
+50,000
+25% +$383K
WBA
23
DELISTED
Walgreens Boots Alliance
WBA
$1.41M 1.58%
45,000
+25,000
+125% +$926K
NWLI
24
DELISTED
National Western Life Group, Inc. Class A
NWLI
$1.37M 1.52%
8,000
– –
KD icon
25
Kyndryl
KD
$2.66B
$1.32M 1.48%
160,000
+20,000
+14% +$208K
1
2 3

Similar funds

AA
Ahara Advisors Jersey City, New Jersey $120M AUM
CC
Commons Capital Needham, Massachusetts $120M AUM 31.45% 1-Year Est. Return
DG
Dala Group Hoffman Estates, Illinois $120M AUM
ACM
AIHC Capital Management Central $120M AUM
WAG
Windsor Advisory Group Columbus, Ohio $120M AUM 4.29% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $120M AUM 52.72% 1-Year Est. Return
IW
Integrated Wealthcare Durham, North Carolina $120M AUM
BCWM
Ball & Co Wealth Management Franklin, Tennessee $120M AUM 21.28% 1-Year Est. Return

CM Management's Q3 2022 Portfolio in Review

As of Q3 2022, CM Management held 74 positions worth $89.6M, down 4.7% from $94M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

CM Management's Q3 2022 filing shows 5 new, 31 increased, 13 reduced and 3 closed positions. Its largest new stake was JPMorgan Chase: 10,000 shares worth $1.04M. The largest sale was Cytokinetics, an estimated $2.41M.

By sector, the portfolio is most concentrated in Healthcare at 37% of assets, down from 39% a quarter earlier, followed by Financials and Energy.

  • CM Management's largest Q3 2022 buy was JPMorgan Chase: 10,000 shares worth $1.04M.
  • CM Management added most to Walgreens Boots Alliance in Q3 2022, an estimated $926K increase.
  • CM Management's biggest Q3 2022 reduction was Cytokinetics, cutting an estimated $2.41M.
  • CM Management fully exited PTC Therapeutics in Q3 2022, selling an estimated $1.8M.
  • CM Management's ten largest holdings make up 37% of its $89.6M portfolio in Q3 2022.
  • CM Management opened 5 new positions and closed 3 in Q3 2022.
  • CM Management's portfolio value fell 4.7% quarter-over-quarter to $89.6M.

Based on CM Management's 13F filing for Q3 2022, filed 4 Nov 2022.